• T2CANDIDA® PANEL Named Best Medical Technology Product

    at the Prix Galien USA 2015 Awards

    Learn More

  • Now the only reason to treat patients for Candida is because they actually have it

    T2Candida demonstrates higher sensitivity than blood culture, which misses 40-50% of Candida infections.

    Learn More

  • Now there’s a brand new weapon in the fight against sepsis. We call it “time.”

    T2Candida delivers faster results, which helps save lives, lower costs and reduce resistance.

    Learn More

  • Pfaller

    T2 Biosystems has done what many said could not be done. Its T2MR technology generates accurate, rapid results using direct sample analysis of whole blood without relying on blood culture. The T2Candida Panel represents how T2MR is the next breakthrough in medical diagnostics, and it has significant potential to save lives and reduce healthcare costs.

    Michael Pfaller, MD, Chief Medical Officer, T2 Biosystems, Lexington, MA, Professor Emeritus, University of Iowa College of Medicine & College of Public Health, Iowa City, IA

  • Clancy

    What we need is a test that is 90% sensitive and 90% specific. That’s the test that makes a difference. If you’re at 90/90 then the negative predictive value is exceptional in virtually every population you use it in...that’s really clinically the most meaningful performance that we can achieve.

    Cornelius J. Clancy, MD, Associate Professor of Medicine, Director, Mycology Program, University of Pittsburgh, Pittsburgh, PA

  • Mylonakis

    The ability to determine the presence or absence of Candida within hours – compared to days – is paradigm changing for patients at risk for these infections.

    Eleftherios Mylonakis, MD, PhD, FIDSA, Chief, Division of Infectious Diseases, Rhode Island Hospital and The Miriam Hospital and Dean's Professor of Medical Science, Alpert Medical School of Brown University, Providence, RI

  • Canon US Life Sciences

    We believe combining our collective expertise with T2 Biosystems' proprietary T2MR platform may enable us to develop a fully differentiated diagnostic panel for the detection of Lyme disease, an area of critical need where delays in providing appropriate treatment to patients can result in significant morbidity and unnecessary costs.

    Akiko Tanaka, President and CEO of Canon U.S. Life Sciences